Foster & Motley Inc. Makes New $244,000 Investment in Henry Schein, Inc. $HSIC

Foster & Motley Inc. acquired a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the second quarter, HoldingsChannel reports. The institutional investor acquired 3,336 shares of the company’s stock, valued at approximately $244,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HSIC. Burgundy Asset Management Ltd. raised its holdings in Henry Schein by 33.9% during the first quarter. Burgundy Asset Management Ltd. now owns 2,235,429 shares of the company’s stock worth $153,105,000 after purchasing an additional 566,530 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in Henry Schein by 24,351.3% during the first quarter. Jones Financial Companies Lllp now owns 542,330 shares of the company’s stock worth $37,144,000 after purchasing an additional 540,112 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Henry Schein by 6.5% during the first quarter. JPMorgan Chase & Co. now owns 6,373,036 shares of the company’s stock worth $436,489,000 after purchasing an additional 390,399 shares in the last quarter. Nuveen LLC purchased a new position in shares of Henry Schein during the first quarter worth approximately $20,857,000. Finally, Hawk Ridge Capital Management LP purchased a new position in shares of Henry Schein during the first quarter worth approximately $19,684,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $62.98 on Monday. The firm’s fifty day moving average price is $67.12 and its 200 day moving average price is $68.60. Henry Schein, Inc. has a 1-year low of $60.56 and a 1-year high of $82.49. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The firm has a market cap of $7.64 billion, a price-to-earnings ratio of 20.32, a price-to-earnings-growth ratio of 2.08 and a beta of 0.81.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.09). Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The firm had revenue of $3.24 billion during the quarter, compared to analysts’ expectations of $3.22 billion. During the same quarter last year, the business earned $1.23 earnings per share. The business’s quarterly revenue was up 3.3% on a year-over-year basis. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. On average, sell-side analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HSIC. Stifel Nicolaus restated a “hold” rating and set a $75.00 target price (down from $80.00) on shares of Henry Schein in a research report on Friday, July 25th. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research report on Wednesday, October 8th. JPMorgan Chase & Co. lowered their target price on shares of Henry Schein from $80.00 to $76.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. UBS Group lowered their target price on shares of Henry Schein from $75.00 to $70.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Finally, Leerink Partners set a $75.00 target price on shares of Henry Schein in a research report on Monday, July 14th. Five investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $76.67.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.